niacinamide has been researched along with Cancer of Gastrointestinal Tract in 13 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluated the efficacy and safety of sorafenib in patients with advanced gastrointestinal stromal tumors (GIST) who failed to previous standard treatments." | 9.16 | Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. ( Im, SA; Kang, BY; Kang, YK; Kwon, HC; Lee, SS; Park, SH; Park, SR; Ryoo, BY; Ryu, MH, 2012) |
| "To report a case of nephrotic syndrome (NS) induced by both sunitinib and sorafenib therapy." | 7.78 | Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. ( Benekli, M; Buyukberber, S; Cetin, B; Guz, G; Inal, S; Memis, L; Ozturk, SC; Turan, N, 2012) |
| "To evaluated the efficacy and safety of sorafenib in patients with advanced gastrointestinal stromal tumors (GIST) who failed to previous standard treatments." | 5.16 | Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. ( Im, SA; Kang, BY; Kang, YK; Kwon, HC; Lee, SS; Park, SH; Park, SR; Ryoo, BY; Ryu, MH, 2012) |
| "To report a case of nephrotic syndrome (NS) induced by both sunitinib and sorafenib therapy." | 3.78 | Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. ( Benekli, M; Buyukberber, S; Cetin, B; Guz, G; Inal, S; Memis, L; Ozturk, SC; Turan, N, 2012) |
| " This phase I trial sought to determine the maximum tolerable dose (MTD) of bevacizumab and sorafenib combined with standard cytotoxic therapy for advanced gastrointestinal (GI) cancers." | 2.82 | Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. ( Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J, 2016) |
| "Both the soft tissue sarcomas and the neuroendocrine tumors are rare diseases." | 2.52 | [Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor]. ( Kato, S, 2015) |
| "Sorafenib was moderately tolerated, and toxicity reported in 56% of the patients." | 1.39 | Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. ( Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Pozzi, V | 1 |
| Campagna, R | 1 |
| Sartini, D | 1 |
| Emanuelli, M | 1 |
| Kato, S | 1 |
| Hubbard, JM | 1 |
| Kim, G | 1 |
| Borad, MJ | 1 |
| Johnson, E | 1 |
| Qin, R | 1 |
| Lensing, J | 1 |
| Puttabasavaiah, S | 1 |
| Wright, J | 1 |
| Erlichman, C | 1 |
| Grothey, A | 1 |
| Park, MA | 2 |
| Mitchell, C | 1 |
| Zhang, G | 1 |
| Yacoub, A | 2 |
| Allegood, J | 1 |
| Häussinger, D | 2 |
| Reinehr, R | 2 |
| Larner, A | 1 |
| Spiegel, S | 1 |
| Fisher, PB | 1 |
| Voelkel-Johnson, C | 2 |
| Ogretmen, B | 2 |
| Grant, S | 2 |
| Dent, P | 2 |
| Yim, KL | 1 |
| Cunningham, D | 1 |
| Italiano, A | 2 |
| Cioffi, A | 1 |
| Coco, P | 1 |
| Maki, RG | 2 |
| Schöffski, P | 1 |
| Rutkowski, P | 2 |
| Le Cesne, A | 1 |
| Duffaud, F | 2 |
| Adenis, A | 1 |
| Isambert, N | 1 |
| Bompas, E | 1 |
| Blay, JY | 2 |
| Casali, P | 1 |
| Keohan, ML | 1 |
| Toulmonde, M | 1 |
| Antonescu, CR | 1 |
| Debiec-Rychter, M | 1 |
| Coindre, JM | 2 |
| Bui, B | 2 |
| Park, SH | 1 |
| Ryu, MH | 1 |
| Ryoo, BY | 1 |
| Im, SA | 1 |
| Kwon, HC | 1 |
| Lee, SS | 1 |
| Park, SR | 1 |
| Kang, BY | 1 |
| Kang, YK | 1 |
| Roubaud, G | 1 |
| Kind, M | 1 |
| Zygulska, AL | 1 |
| Krzemieniecki, K | 1 |
| Sowa-Staszczak, A | 1 |
| Turan, N | 1 |
| Benekli, M | 1 |
| Ozturk, SC | 1 |
| Inal, S | 1 |
| Memis, L | 1 |
| Guz, G | 1 |
| Cetin, B | 1 |
| Buyukberber, S | 1 |
| Montemurro, M | 1 |
| Gelderblom, H | 1 |
| Bitz, U | 1 |
| Schütte, J | 1 |
| Joensuu, H | 1 |
| Trent, J | 1 |
| Bauer, S | 1 |
| Pink, D | 1 |
| Schoental, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Sorafenib in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors Who Failed to Imatinib and Sunitinib[NCT01091207] | Phase 2 | 39 participants (Anticipated) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for niacinamide and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Nicotinamide
Topics: Delayed Diagnosis; Gastrointestinal Neoplasms; Humans; Niacinamide; Nicotinamide N-Methyltransferase | 2022 |
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestin | 2015 |
Targeted drug therapies and cancer.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride | 2011 |
Hypothyroidism during treatment with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles | 2012 |
2 trials available for niacinamide and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2016 |
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Drug Resistance, Neoplasm; Female; Gastrointestina | 2012 |
7 other studies available for niacinamide and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcium; Carboxylic Este | 2010 |
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
Topics: Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; | 2010 |
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenes | 2012 |
Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series.
Topics: Antineoplastic Agents; Benzenesulfonates; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stroma | 2012 |
Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Gastrointestinal Neoplasms; Gastrointestinal Str | 2012 |
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemothe | 2013 |
The role of nicotinamide and of certain other modifying factors in diethylnitrosamine carcinogenesis: fusaria mycotoxins and "spontaneous" tumors in animals and man.
Topics: Animals; Diethylnitrosamine; Female; Fusarium; Gastrointestinal Neoplasms; Genital Neoplasms, Female | 1977 |